Daewoong Pharmaceutical has officially launched the world’s first ring-type continuous blood pressure monitor, “CART BP Pro,” following its recent inclusion in the national health insurance reimbursement scheme.
The company announced on August 27 that the device, developed by SkyLabs, has been approved by the Health Insurance Review and Assessment Service (HIRA) and is now available in the market.
The CART BP Pro addresses the discomfort associated with traditional cuff-based blood pressure monitors, which require upper-arm cuffs and can disrupt daily activities and sleep.
Instead, this ring-type device, worn on the finger, continuously monitors blood pressure for 24 hours using advanced biosensors and AI technology to analyze blood flow and provide accurate readings.
The data is automatically sent to healthcare providers, allowing for precise monitoring of blood pressure fluctuations throughout the day.
The inclusion of CART BP in the insurance reimbursement list is expected to significantly increase accessibility for Korea’s 12 million hypertension patients, reducing their financial burden.
The estimated out-of-pocket cost for patients is expected to be between 5,000 and 9,000 KRW per day. Daewoong Pharmaceutical plans to first distribute the hospital-use model “CART BP Pro” and expand to a consumer version that doesn’t require a prescription by the first half of next year.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, emphasized that the inclusion of CART BP in the insurance reimbursement list marks a significant step forward in the use of digital wearable devices for the prevention and treatment of hypertension.
He added that the company would leverage its marketing experience with other digital healthcare products, such as the Mobicare ECG monitor and the Athea AI ECG analysis software, to drive the market penetration of it.
Editor 메디마스터
Provided by: DAEWOONG
유방암 난소암 가족력? 유전자 검사로 대비하세요. 분당차여성병원이 난소암 및 유방암 가족력이 있는 경우 BRCA(브라카) 유전자…
유년기 아이들 생선 섭취, 이타적 행동과 협력심에 긍정적 영향 — 오메가-3·요오드, 아동 친사회성에도 긍정적 작용…
대웅제약·고대 안암병원, 정밀의료 협력으로 신약개발 혁신 대웅제약(대표 박성수·이창재)은 고려대학교 안암병원 연구부(연구부원장 박범진)와 인공지능(AI)을 활용한 신약…